Who are Amphista Therapeutics's investors?

Amphista Therapeutics's investors include Advent Life Sciences, Novartis Venture Fund, SV Health Investors, Dementia Discovery Fund, European Investment Fund, Forbion, Gilde Healthcare, Redwood Ventures and 1 more.

Where is Amphista Therapeutics headquartered?

Amphista Therapeutics is headquartered in Cambridge, GB.

Amphista Therapeutics

Cambridge, GB · 9 known investors

Find your way into Amphista Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

287 people can intro you to Giles

Ask Anne Horgan to introduce you to Giles Brown

You →Anne · together at Cambridge Biotechnology Ltd →Giles

198 people can intro you to Louise

Ask Jamie Chen to introduce you to Louise Modis

You →Jamie · together at Amphista Therapeutics →Louise

Your email: who you already know at Amphista Therapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Amphista Therapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins. The company designs degraders that combine favorable properties of PROTAC and molecular glue approaches to address a wider range of tissues and disease indications.

Biotech

Founders & leadership

Louise Modis Chief Executive OfficerModis joined Amphista as Chief Scientific Officer in 2023, having previously held the same role at Mogrify. Her earlier career includes several years at GSK, where she served as Scientific Director of the GSK Immunology Network and later as VP heading the Cytokine, Chemokine & Complement Discovery Performance Unit and the Immunology Research Unit, alongside a board seat at Sitryx.

Martin PassChief Development OfficerChief Development Officer at Amphista

Giles Brown Executive VP Drug DiscoveryGiles Brown is Executive VP of Drug Discovery at Amphista Therapeutics and brings over 24 years of medicinal chemistry experience in biotech, including work across small molecules, covalent compounds, and protein degraders, with multiple compounds advancing to clinical development. He has led early-stage drug discovery efforts, guided corporate strategy and fundraising, and worked on structure-based drug design and synthetic organic chemistry.

Investors · 9

Advent Life Scienceslisted by Advent Life SciencesLondon

How we know: Advent Life Sciences's portfolio page · a partner's Signal profile · funding news · press coverage · Not right? Tell us

Novartis Venture Fundlisted by Novartis Venture FundBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · a partner's Signal profile · funding news · Not right? Tell us

SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20M

How we know: SV Health Investors's portfolio page · Not right? Tell us

Dementia Discovery FundreportedLondon

How we know: funding news · press coverage · Not right? Tell us

European Investment FundreportedLuxembourg

How we know: funding news · Not right? Tell us

ForbionreportedNaarden

How we know: funding news · Not right? Tell us

Gilde HealthcarereportedUtrecht · $1.1M – $55M

How we know: funding news · Not right? Tell us

Redwood VenturesreportedGuadalajara

How we know: a partner's Signal profile · Not right? Tell us

Scottish Investment BankreportedGlasgow · $250K – $2M

How we know: funding news · Not right? Tell us

In the news

Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases - Amphista Therapeutics : Amphista Therapeuticsamphista.com · Dec 2022

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets - Amphista Therapeutics : Amphista Therapeuticsamphista.com · Mar 2021

Amphista Therapeutics raises $7.5 million Series A round to advance targeted protein degradation assets in cancer - Amphista Therapeutics : Amphista Therapeuticsamphista.com · Apr 2020

Frequently asked questions

What does Amphista Therapeutics do?: Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins. The company designs degraders that combine favorable properties of PROTAC and molecular glue approaches to address a wider range of tissues and disease indications.
Who are Amphista Therapeutics's investors?: Amphista Therapeutics's investors include Advent Life Sciences, Novartis Venture Fund, SV Health Investors, Dementia Discovery Fund, European Investment Fund, Forbion, Gilde Healthcare, Redwood Ventures and 1 more.
Where is Amphista Therapeutics headquartered?: Amphista Therapeutics is headquartered in Cambridge, GB.